Rethinking Routines in Multiple Sclerosis Management: What the Future Holds for DMTs and Cognitive Assessment Strategies

Multiple sclerosis (MS) is a chronic inflammatory and neurological disease that is the leading cause of disability in young and middle-aged people in the United States. The number of disease-modifying therapies (DMTs) available for treatment of MS has expanded in recent years, and it is imperative that neurologists and other health care professionals (HCPs) have up-to-date knowledge of clinical efficacy and safety of these therapeutic agents to inform individualized treatment decisions.

Cognitive impairment (CI) is common in patients with MS and contributes substantially to disability, loss of employment, and declines in quality of life, yet CI remains underrecognized. Clinicians need to be aware of recent recommendations for routine assessment and management of CI, deficits typical of MS. CI is increasingly being evaluated in clinical trials of MS therapies, and emerging evidence regarding cognitive effects of DMTs and the relationship between CI and other features of MS progression may have important implications for MS management.

This CME Outfitters webcast will feature an expert panel discussion that focuses on the efficacy and safety of recently approved DMTs, implementing cognitive assessment into routine monitoring for patients with MS, and emerging data on the effects of MS therapies on cognition.

- Learning Objectives -

At the end of this CE activity, participants should be able to:
- Apply clinical data on efficacy and safety of recently approved therapies to individualized treatment decisions for patients with MS.
- Incorporate cognitive assessment into routine monitoring for patients with MS.
- Evaluate emerging data on the effects of MS therapies on cognition.

The following learning objectives pertain only to those requesting CNE or CPE credit:
- Examine clinical data on efficacy and safety of recently approved therapies for individualized treatment plans for patients with MS.
- Describe how to incorporate cognitive assessment into routine monitoring for patients with MS.
- Evaluate emerging data on the effects of MS therapies on cognition.